04. December 2019 | 16:10 CET
MagForce AG - systematic development creates trust
MagForce AG, headquartered in Berlin, is a leading company in the field of nanomedicine with a focus on cancer therapy. The so-called NanoTherm therapy developed by it would be suitable for the local treatment of almost all solid tumours. The treatment is carried out using heat generated by activating injected superparamagnetic nanoparticles. The components of this therapy have EU-wide certification for the treatment of brain tumours. The aim of this novel cancer therapy is to establish itself as a further pillar of cancer therapy alongside conventional therapy methods such as surgery, radiation therapy and chemotherapy. According to available data, NanoTherm therapy shows promising efficacy and is also well tolerated.
time to read: 1 minutes by Mario Hose
Notable demand in the USA starting 2021
Magforce AG is covered by GBC and the results for the first six months of 2019 are in line with analysts' expectations. Based on the European roll-out and the expected further development of the MagForce technology for prostate cancer treatment in the US, GBC's experts anticipate an increase in revenues from the coming fiscal year, but significant revenues should not be generated until 2021.
In Germany, the reimbursement of costs is to be promoted, thus increasing the number of treatments. MagForce AG can already report initial successes here. While up to now a patient-specific reimbursement has been obtained, the treatment centers will be able to negotiate the budgets with the health insurance companies in the future due to the increasing number of cases. However, the issue of cost reimbursement will continue to be pursued in the coming financial years.
GBC confirms rating and price target
As there are no changes in the assumptions compared to their last research study dated 10. September 2019, the analysts of GBC confirm their sales and earnings forecasts. According to their expectations, the break-even point at all earnings levels should not be reached until the strong sales increase following the approval for prostate cancer treatment in the USA in the financial year 2021. On the basis of the unchanged forecasts and the unchanged DCF valuation model, they confirm the price target of EUR 13.50. Based on the current share price, they thus continue to award the BUY rating.